Altshuler Shaham’s Xenon Pharmaceuticals XENE Stock Holding History

Altshuler Shaham’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-42,000	Closed	-$1.28M	–	545
2022 Q2	$1.28M	Hold	42,000	–	–	0.02%	70
2022 Q1	$1.28M	Sell	42,000 -11,600	-22%	-$347K	0.01%	139
2021 Q4	$1.67M	Hold	53,600	–	–	0.01%	144
2021 Q3	$823K	Buy	+53,600	New	+$931K	0.01%	176
2020 Q4	–	Sell	-151,235	Closed	-$1.67M	–	475
2020 Q3	$1.67M	Hold	151,235	–	–	0.04%	66
2020 Q2	$1.9M	Hold	151,235	–	–	0.06%	43
2020 Q1	$1.72M	Buy	151,235 +29	+0%	+$413	0.08%	37
2019 Q4	$1.98M	Hold	151,206	–	–	0.06%	47
2019 Q3	$1.35M	Buy	151,206 +1,448	+1%	+$13.7K	0.05%	52
2019 Q2	$1.48M	Buy	149,758 +6,151	+4%	+$58.9K	0.06%	54
2019 Q1	$1.46M	Buy	143,607 +45,600	+47%	+$387K	0.07%	71
2018 Q4	$618K	Buy	+98,007	New	+$871K	0.03%	100

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Altshuler Shaham's XENE Position: Q3 2022 in Review

Altshuler Shaham sold out of Xenon Pharmaceuticals (XENE) in Q3 2022, closing a stake of 42,000 shares — an estimated $1.28M sold.

Altshuler Shaham first reported a position in XENE in Q4 2018 and held it in 12 quarters. The position peaked at $1.98M in Q4 2019. 154 funds tracked by Wall St. Rank hold XENE as of Q3 2022.

Altshuler Shaham reported no remaining Xenon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Altshuler Shaham sold 42,000 Xenon Pharmaceuticals shares in Q3 2022, an estimated $1.28M.
Altshuler Shaham first reported a position in Xenon Pharmaceuticals in Q4 2018 and held it in 12 quarters.
Altshuler Shaham's Xenon Pharmaceuticals position peaked at $1.98M in Q4 2019.
154 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2022.

Based on Altshuler Shaham's 13F filing for Q3 2022, filed 14 Nov 2022.